Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-25 of 149 for your search:
Start Over
Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer
Status: Active
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CL-PTL-119, NCI-2015-01040, NCT02346747
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 65
Trial IDs: 020221, NCI-2010-00822, NCT00045968
Study of a Melanoma Vaccine in Stage IIb, IIc, and III Melanoma Patients
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 103A-301, NCI-2012-01351, NCT01546571
Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: SP005, NCI-2014-02085, 2012-002814-38, NCT02111577
Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: ICT-107-301, NCI-2015-01811, NCT02546102
Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: JX594-HEP024, NCI-2016-00198, NCT02562755
Vaccine Therapy in Treating Patients with Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
Status: Enrolling by invitation
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 6304, NCI-2016-00895, NCT00194714
Vaccine Therapy with or without Cyclophosphamide in Treating Patients with Recurrent or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC038C, NCI-2009-01194, Mod06-005263-65, MAYO-MC038C, MAYO-06-005263, NCT00450814
Vaccine Therapy in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC29810, NCI-2011-00285, NCT01312389
Vaccine Therapy and Lenalidomide in Treating Patients With B-Cell Chronic Lymphocytic Leukemia
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: H-30087, NCI-2013-01015, RV-CLL-PI-0715, TAIL, NCT01604031
Vaccine Therapy in Treating Patients With Stage I-III Non-Small Cell Lung Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 11-094, NCI-2013-00081, NCT01720836
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: BP-HM-001, NCI-2013-00518, NCT01744223
Vaccine Therapy with or without Polysaccharide-K in Treating Patients with Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 7866, NCI-2013-01377, 135, 7866/135, NCT01922921
Vaccine Therapy and Iscomatrix with or without Cyclophosphamide and Celecoxib in Treating Patients with Thoracic Malignancies or Tumors That Have Spread to the Chest Cavity
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-C-0053, NCI-2014-02465, 140053, 348360, P131392, NCT02054104
Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 3 months to 21 years
Trial IDs: BP-004, NCI-2015-01890, NCT02065869
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-701-0114, NCI-2014-01008, NCT02078648
A Study of INO-3112 DNA Vaccine With Electroporation in Patients With Cervical Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: HPV-004, NCI-2015-00497, NCT02172911
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS001-04, NCI-2015-01212, NCT02291055
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Patients With Prostate Cancer - KEYNOTE-046
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS142-03, NCI-2015-02095, NCT02325557
Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 164-05, NCI-2015-02102, NCT02386501
Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the Rectum
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: ADXS001-06, NCI-2015-01897, NCT02399813
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
Chemoimmunotherapy and Vaccine Therapy in Treating Patients with Recurrent Ovarian Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 11-128, NCI-2015-00800, 11-128, NCT02432378
A Phase 1/2, Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ASN002-101, NCI-2015-01866, NCT02440685
Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NLG0401, NCI-2016-00186, 1504-1393, NCT02460367
Start Over